India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Thursday the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg in the United States following US FDA approval of its Abbreviated New Drug Application.
The product is bioequivalent to Azurity Pharmaceuticals Inc's Edarbii, and is indicated for the treatment of hypertension in adults to lower blood pressure.
Lupin says that it is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.
Azilsartan Medoxomil Tablets (RLD Edarbi) had estimated annual sales of USD53.5m in the US (IQVIA MAT April 2026)
AstraZeneca secures US approval for Truqap combination in PTEN‑deficient prostate cancer
Transcend Therapeutics acquired by Otsuka Pharmaceutical
Rocket Pharmaceuticals closes USD180m Rare Pediatric Disease voucher sale
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Precigen and the RRPF recognise International RRP Awareness Day
Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS
FDA grants priority review for Genentech's Tecentriq in stage III dMMR/MSI-H colon cancer
Formosa Pharmaceuticals signs Vietnam licensing deal with Samil Pharmaceuticals
Harbour BioMed IND for HBM7004 accepted by China's NMPA
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
FDA grants rare paediatric disease designation to RedHill's opaganib
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector